ArticleScientific reports2025
Knockdown of PATZ1 alleviates chronic heart failure through the USP22/HIF-1α axis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of ubiquitin‑specific peptidase 22 in cellular fate: From embryonic survival to tissue repair, inflammation and metabolism (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The pathogenesis of chronic heart failure (CHF) is complex and not fully understood. HIF-1α plays a paradoxical role in CHF, and its stability is regulated by the deubiquitinating enzyme USP22. However, the role of USP22 in CHF and its upstream regulatory mechanisms remain unclear. This study aims to investigate the role and regulatory mechanism of the PATZ1/USP22/HIF-1α axis in CHF pathogenesis. An in vitro CHF model was established using angiotensin II (Ang II)-induced H9c2 cardiomyocytes and an in vivo model was created by abdominal aortic constriction (AAC) in rats. Genetic manipulations were performed using shRNAs or overexpression plasmids. Cell viability and cardiac function were assessed by CCK-8, TUNEL staining, Western blot, immunohistochemistry, and hemodynamic measurements. Protein interactions, stability, and transcriptional regulation were analyzed via co-immunoprecipitation (Co-IP), ubiquitination assays, cycloheximide (CHX) chase assays, chromatin immunoprecipitation-qPCR (ChIP-qPCR), and dual-luciferase reporter assays. USP22 was significantly upregulated in human CHF datasets (GSE116250/GSE57345) and experimental models. USP22 knockdown reduced cardiomyocyte injury in vitro (increased viability, decreased apoptosis) and improved cardiac function in vivo (increased LVSP, decreased LVEDP, and reduced fibrosis). Mechanistically, USP22 bound to and stabilized HIF-1α protein by deubiquitination. HIF-1α overexpression reversed USP22 knockdown-mediated cardioprotection. Furthermore, PATZ1, which was upregulated in CHF, transcriptionally activated USP22 by binding to its promoter. PATZ1 silencing attenuated cardiac injury, while USP22 co-overexpression abrogated this protective effect by restoring HIF-1α levels. PATZ1 promotes CHF progression by transcriptionally upregulating USP22, which stabilizes HIF-1α via deubiquitination. Targeting the PATZ1/USP22/HIF-1α axis may offer novel therapeutic strategies for CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.